Table 1 Parameters of thrombodynamics in the COVID-19 patients.
From: Altered platelet and coagulation function in moderate-to-severe COVID-19
Comparison groups and subgroups | Parameters of thrombodynamics | ||||
|---|---|---|---|---|---|
Stationary rate of clot growth, μm/min | Lag time, min | Initial rate of clot growth, μm/min | Clot size, μm | Clot density, a.u | |
(a) Patients with COVID-19 and healthy donors | |||||
Patients with COVID-19 (n = 200) | 25 (18; 32) | 1.3 (1.1; 1.6)*** | 54 (50; 60) | 1103 (901; 1253) | 29,100 (24,900; 32,800)** |
Healthy subjects (n = 20) | 28 (26; 30) | 0.9(0.8; 1.0) | 51 (50; 55) | 1122 (1057; 1175) | 25,800 (21,000; 28,300) |
(b) Dependence on the outcome of the disease | |||||
Favorable (n = 184) | 25.3 (18.2; 32.1)* | 1.3 (1.1; 1.5) | 54.7 (49.9; 59.8)* | 1108 (917; 1279)** | 29,000 (24,800; 31,600)* |
Fatal (n = 16) | 20.1 (15.4; 25.2) | 1.3 (1.1; 1.7) | 50.2 (45.1; 53.2) | 910 (871; 1055) | 32,100 (28,300; 34,800) |
(c) Dependence on the severity of the disease | |||||
Moderate severity (n = 149) | 25.5 (18.0; 32.2) | 1.3 (1.1; 1.5) | 54.9 (49.9; 59.7) | 1130 (909; 1288)** | 29,000 (25,200; 31,500) |
Severe (n = 51) | 25.5 (18.0; 32.2) | 1.3 (1.2; 1.6) | 52.2 (49.2; 57.8) | 985 (881; 1118) | 29,500 (24,100; 32,800) |
(d) Dependence on the presence of concomitant hematologic neoplasms | |||||
Neoplasms (n = 8) | 32.3* (24.9; 35.8) | 1.1 (0.9; 1.3) | 66.4 (55.8; 68.4)** | 1364 (1109; 1449)** | 26,100 (24,400; 29,400) |
No neoplasms (n = 207) | 24.9 (17.0; 31.4) | 1.3 (1.1; 1.6) | 53.9 (49.3; 59.6) | 1098 (894; 1238) | 29,100 (25,000; 31,900) |
(e) Dependence on the level of C-reactive protein in blood serum | |||||
< 10 mg/l (n = 23) | 32.1 (21.2; 36.5)* | 1.1 (1.0; 1.2)** | 61.3 (50.9; 66.5)** | 1276 (930; 1408)* | 27,000 (23,300; 29,700)** |
> 10 mg/l (n = 114) | 23.9 (17.6; 28.7) | 1.3 (1.1; 1.5) | 54.0 (49.8; 58.9) | 1082 (917; 1183) | 30,400 (26,400; 32,600) |
